# SDGR catalysts: Schrodinger, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sdgr/catalysts

> Schrodinger, Inc. (SDGR) has no upcoming catalysts in this calendar. The latest recorded is the Schrodinger, Inc. earnings report, November 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Schrodinger, Inc. |
| Ticker | SDGR (Nasdaq) |
| SEC CIK | 1490978 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sdgr |

## Cash runway

Cash $366.4M as of 2026-09-30; quarterly burn $47.6M; about 23.1 months of runway at that rate (XBRL company facts, accession 0001490978-26-000076).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2024 | [Dinger trial start](https://sec-api.dev/pdufa/dinger) | SDGR | advanced solid tumors | completed | "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000076/sdgr-20260930.htm)) |
| November 12, 2024 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097824000088/sdgr-20240930xexx991xscena.htm)) |
| February 26, 2025 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000013/sdgr-20241231xexx991.htm)) |
| Q2 2025 | [SGR-1505 interim data readout](https://sec-api.dev/pdufa/sgr-1505) | SDGR | relapsed/refractory B-cell malignancies | scheduled | "•Schrödinger continues to progress the Phase 1 clinical study of SGR-1505, the company's MALT1 inhibitor, in patients with relapsed/refractory B-cell malignancies and expects to report initial clinical data from the trial in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000013/sdgr-20241231xexx991.htm)) |
| May 7, 2025 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Strong First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000058/sdgr-20250331xexx991.htm)) |
| July 15, 2025 | [Schrodinger, Inc. PDUFA date](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000076/sdgr-20260930.htm)) |
| August 6, 2025 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm)) |
| Q4 2025 | [Dinger interim data readout](https://sec-api.dev/pdufa/dinger) | SDGR |  | delayed | "Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm)) |
| Q4 2025 | [SGR-2921 interim data readout](https://sec-api.dev/pdufa/sgr-2921) | SDGR | AML and myelodysplastic syndrome | scheduled | "Initial clinical data from this study are expected in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm)) |
| November 5, 2025 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/sdgr-20250930xexx991.htm)) |
| February 25, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000009/sdgr-20251231xexx991.htm)) |
| Q2 2026 | [Dinger interim data readout](https://sec-api.dev/pdufa/dinger) | SDGR |  | scheduled | "We anticipate reporting initial data from the trial in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/sdgr-20251231.htm)) |
| May 5, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000036/sdgr-20260331x8kxexx991.htm)) |
| August 5, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000067/sdgr-20260630x8kxexx991.htm)) |
| November 4, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000075/sdgr-20260930x8kxexx991.htm)) |

## Drugs

- [Dinger](https://sec-api.dev/pdufa/dinger): advanced solid tumors
- [SGR-1505](https://sec-api.dev/pdufa/sgr-1505): relapsed/refractory b-cell malignancies
- [SGR-2921](https://sec-api.dev/pdufa/sgr-2921): aml and myelodysplastic syndrome

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sdgr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SDGR catalysts: Schrodinger, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sdgr/catalysts

```bibtex
@misc{secapidev_companies_sdgr_catalysts_20261116,
  title        = {SDGR catalysts: Schrodinger, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sdgr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sdgr_catalysts_20261116","title":"SDGR catalysts: Schrodinger, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sdgr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
